How Technology Can Help Overcome Barriers to Getting Effective Therapies into Patients with Ultra Rare Disorders
Healthcare IT Today
SEPTEMBER 28, 2022
Already, this real-world, distributed time of diagnosis approach, has been used to cut down more than four years of estimated drug development timeline in the instance of PRAX-222, a new therapy for SCN2A, a rare genetic disorder of pediatric epilepsy. Editor’s Note: You can support Lucy’s GoFundme.
106 
Let's personalize your content